Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China.
<h4>Background</h4>Sunitinib was approved several years ago as a first-line drug for treating metastatic renal cell carcinoma (mRCC); however, its high price and broad side effects when administered at the standard dose have limited its clinical use. A clinical trial (NCT02072031) confir...
Main Authors: | Jingyang Lin, Qingxia Fang, Xiaochun Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0281402 |
Similar Items
-
The role of sunitinib in the therapy of metastatic renal cell carcinoma
by: I. G. Rusakov, et al.
Published: (2020-07-01) -
Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
by: Ridhima Iyer, et al.
Published: (2017-01-01) -
Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
by: Ong, Teng Aik, et al.
Published: (2018) -
Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
by: Shibin Zhu, et al.
Published: (2022-10-01) -
Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
by: Predrag Nikic, et al.
Published: (2022-06-01)